We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Protease Inhibitor Therapy in HIV-Infected Children.
- Authors
Feingold, Anat R.; Rutstein, Richard M.; Meislich, Debrah; Brown, Teneille; Rudy, Bret J.
- Abstract
We reviewed the short-term response to and safety of protease inhibitor (PI) therapy in HIV-infected children by performing a retrospective chart review of open-label PI containing combination therapy at two urban pediatric HIV centers. Seventy HIV-infected children received 101 PI containing antiretroviral therapy (ART) combinations. Main outcome measures were follow-up CD4 counts, viral loads, and patient or caregiver reported compliance. During follow-up, treatment with PI ART was associated with a mean maximal increase in CD4[sup +] lymphocyte count of 454 × 10[sup 6]/L and a mean maximal decrease in viral load of 1.76 log units. Of the 32 patients who achieved undetectable viral loads, 28 (87.5%) remained undetectable through a mean follow-up of 8.9 months. Patients who reported good compliance achieved a higher rate of response (92.6%) than those who reported poor compliance (61.5%). Of 14 changes made to a second PI because of treatment failure, 11 (78.6%) resulted in a positive response to the second regimen. Nineteen of 101 courses of PI therapy resulted in significant side effects, including renal complications in 8 of 21 patients treated with indinavir. PI ART was associated with substantial short-term improvement in immunological and virological parameters in this heavily pretreated cohort, with 40% of patients maintaining an undetectable viral load after 9 months of therapy. Patients who failed one PI regimen usually responded to a second regimen. There was a significant rate of side effects from PI treatment.
- Subjects
PROTEASE inhibitors; HIV infections; AIDS treatment; CD4 antigen; VIRAL antigens
- Publication
AIDS Patient Care & STDs, 2000, Vol 14, Issue 11, p589
- ISSN
1087-2914
- Publication type
Article
- DOI
10.1089/10872910050193761